Impact of Study Partner Type on Participant Retention Across Global Regions in the Tauriel and Lauriet Trials for Alzheimer’s Disease

Documenti analoghi

• Robustness and generalizability of a speech‐based digital biomarker derived from recordings of the Clinical Dementia Rating (CDR) interview
  di: Michael J Spilka, et al.
  Pubblicazione: (2024)
• Development and validation of speech‐based biomarkers for measuring clinical progression in AD clinical trials
  di: Michael J. Spilka, et al.
  Pubblicazione: (2025)
• Assessment of Association of Tau PET Spatial Patterns with Cognitive Domains in Participants with Early Alzheimer's Disease in the Phase 2 Auτonomy Trial
  di: Ziad S. Saad, et al.
  Pubblicazione: (2025)
• Exploring Characteristics Predictive of Willingness to Participate in Preclinical Alzheimer’s Disease Trials
  di: Adam I Birnbaum, et al.
  Pubblicazione: (2025)
• CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti‐tau antibody semorinemab
  di: Cosme Sandoval, et al.
  Pubblicazione: (2024)